| Protocol No. | RTOG-0938 | Principal Investigator | Roach III, Mack |
| Phase | II (Cancer Control) |
| Age Group | Adult | Scope | National |
| Secondary Protocol No. | 0938 |
| Title | A Randomized Phase II Trial Of Hypofractionated Radiotherapy For Favorable Risk Prostate Cancer |
| Objective | To demonstrate that 1-year health-related quality of life (HRQOL) for at least one hypofractionated arm is not significantly lower than baseline as measured by the Bowel and Urinary domains of the Expanded Prostate Cancer Index Composite (EPIC) instrument. |
|
|
| Key Eligibility | * Histologically confirmed diagnosis of adenocarcinoma of the prostate
* No evidence of distant metastases
* No regional lymph node involvement |
| Applicable Disease Sites | Prostate |
|
| Therapies Involved | Radiotherapy |
|
| Status | Open |
| Participating Institutions | Mt. Zion : Frances Zhang
Parnassus : Frances Zhang |
|
| Eligibility Document | RTOG-0938_CTGovEligibility_NCT01434290.doc |
|
| Contact | Frances Zhang |
Phone:415-353-9857
Pager:
Email:fzhang@radonc.ucsf.edu |